METTL22

Across TCGA pan-cancer cohorts, METTL22 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated METTL22 data layer compared with 6 for mutation status.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher METTL22 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated METTL22 expression acts as an unfavorable survival marker, although some lineages such as BRCA and READ show a favorable association.

KIRC, ACC, and STAD are the cancer types where METTL22 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Tertile	All	0.533	0.711	<.001	116	view →
ACC	DFS	Median	All	0.408	0.750	<.001	82	view →
STAD	DFS	Quartile	II,III,IV	0.541	0.861	.001	46	view →
BRCA	OS	Tertile	III,IV	0.733	0.504	.003	42	view →
MESO	OS	Tertile	III,IV	0.489	0.705	.005	36	view →
LGG	DFS	Tertile	All	0.646	0.803	<.001	36	view →
LUSC	DFS	Median	III,IV	0.227	0.506	.005	26	view →
PRAD	DFS	Tertile	All	0.705	0.915	<.001	24	view →
THCA	OS	Quartile	IV	0.539	0.910	.012	19	view →
UVM	OS	Tertile	III,IV	0.372	1.000	.002	18	view →
CHOL	DFS	Tertile	III,IV	0.163	0.779	.024	18	view →
BLCA	DFS	Quartile	All	0.186	0.439	.019	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

METTL22–KIRC (DFS)

Open the KIRC breakdown →